Economic assessment of eltrombopag in the treatment of thrombocytopenia. - Wikidata - wikimedia - TriplyDB

Economic assessment of eltrombopag in the treatment of thrombocytopenia.

Economic assessment of eltrombopag in the treatment of thrombocytopenia.

http://www.wikidata.org/entity/Q33424436

about

Modelling cost-effectiveness and health gains of a "universal" vs. "prioritized" HCV treatment policy in a real-life cohort.

P2860

Q40121053-7448E010-AA13-4C4A-AD32-81AB074594BB

P2860

Economic assessment of eltrombopag in the treatment of thrombocytopenia.

http://www.wikidata.org/entity/Q33424436

description

2015 nî lūn-bûn

@nan

2015 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Economic assessment of eltrombopag in the treatment of thrombocytopenia.

@ast

Economic assessment of eltrombopag in the treatment of thrombocytopenia.

@en

type

label

Economic assessment of eltrombopag in the treatment of thrombocytopenia.

@ast

Economic assessment of eltrombopag in the treatment of thrombocytopenia.

@en

prefLabel

Economic assessment of eltrombopag in the treatment of thrombocytopenia.

@ast

Economic assessment of eltrombopag in the treatment of thrombocytopenia.

@en

P1433

Q33424436-8F845AF3-C71C-4993-AA9C-7AAD8E7DC6D9

P1476

Q33424436-809EE03E-73E4-4C98-93E9-7666541C892B

P2093

Q33424436-0B7ED916-7E0B-412D-94A0-98706BD80B3C

Q33424436-362B285C-9EA7-4CA0-BF38-9FD157A12222

Q33424436-57A4A7A1-196C-4B61-A6A1-D5420F8820FA

Q33424436-7DA58FD1-46F1-4865-8E1D-B0566CD8C007

Q33424436-8FF3EA41-EF4A-4FCF-A0C4-078E0C5B6D04

Q33424436-BC688BE9-9CBD-45CE-A68A-823765ED742C

Q33424436-C30F7FC9-F425-4047-AD45-C1AF224596A3

P2860

Q33424436-36F4CEED-CDFF-45FE-AE95-0FCA6FCB6662

Q33424436-3D3CCD2D-A70E-47FC-87EC-86CA8AA693B9

Q33424436-52EA81C4-49D9-4EA5-BCB1-12D8439290C7

Q33424436-536988FD-BF95-4EB0-B7E4-4CDB8EA692C5

Q33424436-561AF824-4A12-4754-BADC-595C0B7693DC

Q33424436-65C3200A-5ABF-418A-99B1-89800D7F864A

Q33424436-6EFD5344-7423-49F4-B319-5D49F56CB9C9

Q33424436-761894E8-29CE-457F-9A71-830DDC4C2DD8

Q33424436-895F99C3-85ED-4633-9F80-77902216F8AD

Q33424436-8AD02511-BAA9-42CC-A470-BE4CB55033C2

P304

Q33424436-EBBBAD9F-0F07-401D-B0F9-D979DCF1A0C7

P31

Q33424436-C930FCB8-E102-4E3A-B8AB-F7C33355475B

P356

Q33424436-29018606-F075-4FFB-9C66-2A669E450BB8

P433

Q33424436-1261B09B-40B0-49A4-80E1-7C1E74735C7F

P478

Q33424436-F109A091-3247-4D1C-8514-658BCC97236C

P50

Q33424436-6CFE74DF-6A2E-4AD1-821F-54FF4E35EE1C

Q33424436-83E5C4A5-2A21-4FA1-A14A-CFE82351E006

P577

Q33424436-04752452-7F68-4050-9DE0-5D56DA821FCC

P698

Q33424436-B8D5C7B7-2C63-426D-8BA4-0FE5402EA8F5

P921

Q33424436-ED092A27-ED89-4432-9149-3757729A98F3

P356

14737167.2015.1028373

P1433

Expert Review of Pharmacoeconomics & Outcomes Research

P1476

Economic assessment of eltrombopag in the treatment of thrombocytopenia.

@en

P2093

Brigida Eleonora Annichiarico

http://www.w3.org/2001/XMLSchema#string

Dario Sacchini

http://www.w3.org/2001/XMLSchema#string

Federica Romano

http://www.w3.org/2001/XMLSchema#string

Francesco Rodeghiero

http://www.w3.org/2001/XMLSchema#string

Marco Marchetti

http://www.w3.org/2001/XMLSchema#string

Matteo Ruggeri

http://www.w3.org/2001/XMLSchema#string

Silvia Coretti

http://www.w3.org/2001/XMLSchema#string

P2860

HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

Evolving epidemiology of hepatitis C virus

Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C.

Peripheral blood cytopaenia limiting initiation of treatment in chronic hepatitis C patients otherwise eligible for antiviral therapy.

Eltrombopag for the treatment of chronic immune or idiopathic thrombocytopenic purpura: a NICE single technology appraisal.

Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy.

Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation.

Outcome of sustained virological responders with histologically advanced chronic hepatitis C.

A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C.

P304

713-720

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/14737167.2015.1028373

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P50

Edoardo G. Giannini

Dario Lidonnici

P577

2015-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26176754

http://www.w3.org/2001/XMLSchema#string

P921

thrombocytopenia